MariMed (OTCMKTS:MRMD) Releases Quarterly Earnings Results, Meets Estimates

MariMed (OTCMKTS:MRMD) issued its quarterly earnings results on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01), Zacks reports. MariMed had a negative net margin of 8.94% and a negative return on equity of 5.85%. The company had revenue of $39.48 million during the quarter, compared to analyst estimates of $38.75 million.

MariMed Price Performance

MRMD stock opened at $0.08 on Thursday. The company has a debt-to-equity ratio of 1.44, a quick ratio of 0.38 and a current ratio of 1.00. The firm has a 50 day moving average price of $0.08 and a 200-day moving average price of $0.09. MariMed has a 52-week low of $0.06 and a 52-week high of $0.23. The firm has a market capitalization of $33.51 million, a price-to-earnings ratio of -2.80 and a beta of 1.33.

About MariMed

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.